Clinical Trial Update: Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC [Phase 2]

View source ↗

Summary

A Phase II study assessing safety and efficacy of crizotinib in East Asian patients with ROS1-positive, ALK-negative advanced non-small cell lung cancer has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Non Small Cell Lung Cancer, ROS1 Proto Oncogene | Phase 2 | Status: COMPLETED | Results posted: 2016-08-01